Biotech Values

[biocqr]

AAVL > There was a loss of 9.3 letters in the control but only 4 rescue injections over 10 mos...seems odd. I'm guessing a large part of the declines in the control group came towards the end of the trial. Plus we don't know what baseline was of the pts prior to starting their prior anti-VEGF therapy...or who knows what their prior therapy response was...or how many had become refractory etc.